ByteDance’s $290 Million AI Drug Bet: Inside Anew Labs, the $1.5 Billion Spin-Off Using Artificial Intelligence to Accelerate the Hunt for New Medicines

ByteDance, the technology company best known for TikTok, is making a much bigger move into artificial intelligence for science. Its newly spun-off AI drug-discovery company, Anew Labs, has raised $290 million in its first external financing round and reached a valuation of $1.5 billion. ByteDance will retain a 56% stake, keeping control while opening the business to major outside investors.

In this episode of The Daily AI Chat, we break down what the deal means, why investors are pouring capital into AI-powered biotechnology, and how a consumer-internet giant could become an important player in the search for new medicines. The round was led by HSG, formerly Sequoia China, IDG Capital and Hillhouse Investment, with 5Y Capital as a co-lead. Gaorong Ventures, Primavera Venture Partners, Boyu Capital, SBP Group and the state-backed Shanghai Future Industries Fund also participated.

Anew Labs is based in Shanghai and uses artificial intelligence to support drug discovery and biological research. The spin-off matters because pharmaceutical development operates on very different timelines and economics from apps, advertising and social media. Drug candidates require years of laboratory work, testing, clinical trials and regulatory review. By separating Anew Labs from its core operations, ByteDance can give the team its own financing structure, specialized management and a clearer path to commercial partnerships.

We examine the opportunity and the risks behind the headline. AI can help researchers analyze proteins, identify promising targets, design molecules and narrow the enormous search space involved in early-stage drug development. That may reduce wasted experiments and help scientific teams move faster. But a strong model or an impressive laboratory result is not the same as an approved medicine. The real test is whether Anew Labs can translate computational predictions into safe, effective treatments that succeed in clinical trials.

The episode also explores why the investor lineup matters, what ByteDance’s retained majority stake says about its long-term ambitions, and how AI-for-science is becoming a strategic frontier in the global technology competition. As foundation models expand beyond text, companies are racing to apply machine learning to chemistry, biology, materials and medicine. The Anew Labs financing is a sign that this race is moving from research programs into independently funded businesses with billion-dollar valuations.

What should listeners watch next? Key signals include the company’s drug pipeline, research partnerships, clinical milestones, hiring, computing strategy and any evidence that its AI systems can produce better candidates faster than conventional approaches. The funding gives Anew Labs resources and credibility, but biotech success will ultimately be measured by scientific results rather than valuation.

Source: Reuters, September 16, 2026. Reporting by Kane Wu in Hong Kong, with additional reporting by Yantoultra Ngui and editing by Muralikumar Anantharaman.

The Daily AI Chat turns the day’s most consequential artificial-intelligence stories into clear, energetic conversations about technology, business, policy and the future. Follow the show for concise analysis of the forces reshaping AI—and the world around it.